Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy

Gut

Volumn 58, Issue 2, 2009, Pages 314-316

  Liu, C H ^a   Liang, C C ^b   Liu, C J ^a   Tsai, H B ^c   Hung, P H ^d   Hsu, S J ^a   Chen, S L ^a   Lin, J W ^a   Lai, M Y ^a   Chen, J H ^a   Chen, P J ^a   Chen, D S ^a   Kao, J H ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; PEGINTERFERON ALPHA2A; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; VIRUS RNA;

ANEMIA; DIALYSIS; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERSTITIAL PNEUMONIA; LETTER; LOW DRUG DOSE; MONOTHERAPY; OPTIC NEURITIS; PRIORITY JOURNAL; RETREATMENT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84984549622     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.165076     Document Type: Letter

References (10)

1. Fabrizi F Poordad FF Martin P. Hepatitis C infection the patient with end-stage renal disease. Hepatology 2002;36:3-10.
2. APASL Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J astroenterol Hepatol 2007;22:615-33.
3. Liu CH, Liang CC, Lin JW, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008;57:525-30.
4. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: etfects of dose and duration. Hepatology 1996;24:778-89.
5. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000:343:1666-72.
6. Sherman M, Yoshida EM, Deschenes M, et al. Canadian Pegasys Study Group. Peginterferon alfa-2a (40 kD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006;55:1631-8.
7. Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006;13:316-21.
8. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa- 2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007,46:768-74.
9. van Leusen R, Adang RP, de Vries RA, et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008;23:721-5.
10. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGASYS International Study Group. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.